Myelofibrosis (MF) is a myeloproliferative disorder that exhibits considerable biological and
clinical heterogeneity. At the two ends of the disease spectrum are the myelodepletive or …

Simple Summary Myelofibrosis is an aggressive bone marrow cancer whose clinical
presentation can be extremely heterogenous. Two distinct phenotypes, myeloproliferative …

We describe 1000 patients with essential thrombocythemia seen at the Center Research
and Innovation of Myeloproliferative Neoplasms (CRIMM), Florence, Italy, between 1980 …

The current retrospective study involving a total of 1607 patients was designed to identify
clinical and molecular variables that were predictive of inferior myelofibrosis‐free survival …

Arterial (AT) and venous (VT) thrombotic events are the most common complications in
patients with polycythemia vera (PV) and are the leading causes of morbidity and mortality …

Classic Philadelphia-negative myeloproliferative neoplasms (MPN) include polycythemia
vera (PV), essential thrombocythemia (ET), and myelofibrosis (MF), classified as primary …

Contemporary risk models in primary myelofibrosis (PMF) include the mutation (MIPSS70)
and mutation/karyotype enhanced (MIPSS70 plus/v2. 0) international prognostic scoring …

The classical BCR:: ABL1-negative myeloproliferative neoplasms such as polycythemia vera
(PV), essential thrombocythemia (ET), and myelofibrosis (MF) are clonal diseases with the …

Polycythemia vera belongs to myeloproliferative neoplasms, essentially by affecting the
erythroblastic lineage. JAK2 alterations have emerged as major driver mutations triggering …

Philadelphia chromosome-negative myeloproliferative neoplasms (MPN) are clonal
disorders of a hematopoietic stem cell, characterized by an abnormal proliferation of largely …